

CLAIMS

1

1 1. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:

3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
4 1; and

5 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
6 2;

7 wherein the medicament is formulated to be administered subcutaneously as a first
8 dose of the antibody on week 0 and a subsequent dose at every 12 weeks thereafter;

9 wherein the medicament is formulated to be administered as a subsequent dose at
10 every 12 weeks at least up to 52 weeks; and

11 wherein the medicament is formulated to result in at least 20% improvement from
12 baseline value of tender joint count and swollen joint count.

1 2. The use according to claim 1, wherein the medicament is formulated to further result
2 in at least 20% improvement from baseline for at least three of the five parameters selected
3 from the group consisting of (i) Physician Global Assessment of disease activity, (ii) Patient
4 Global Assessment of disease activity, (iii) Patient pain assessment, (iv) patient self-assessed
5 disability, and (v) acute-phase CRP.

1 3. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:

3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
4 1; and

5 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
6 2;

7 wherein the medicament is formulated to be administered subcutaneously as a first
8 dose of the antibody on week 0 and a subsequent dose at every 12 weeks thereafter;

9 wherein the medicament is formulated to be administered as a subsequent dose at
10 every 12 weeks at least up to 52 weeks; and

11 wherein the medicament is formulated to result in at least 50% improvement from
12 baseline value of tender joint count and swollen joint count.

1 4. The use according to claim 3, wherein the medicament is formulated to further result
2 in at least 50% improvement from baseline for at least three of the five parameters selected
3 from the group consisting of (i) Physician Global Assessment of disease activity, (ii) Patient
4 Global Assessment of disease activity, (iii) Patient pain assessment, (iv) patient self-assessed
5 disability, and (v) acute-phase CRP.

1 5. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:

3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
4 1; and

5 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
6 2;

7 wherein the medicament is formulated to be administered subcutaneously as a first
8 dose of the antibody on week 0 and a subsequent dose at every 12 weeks thereafter;

9 wherein the medicament is formulated to be administered as a subsequent dose at
10 every 12 weeks at least up to 52 weeks; and

11 wherein the medicament is formulated to result in at least 70% improvement from
12 baseline value of tender joint count and swollen joint count.

1 6. The use according to claim 5, wherein the medicament is formulated to further result
2 in at least 70% improvement from baseline for at least three of the five parameters selected
3 from the group consisting of (i) Physician Global Assessment of disease activity, (ii) Patient
4 Global Assessment of disease activity, (iii) Patient pain assessment, (iv) patient self-assessed
5 disability, and (v) acute-phase CRP.

1 7. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:

3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
4 1; and

5 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
6 2;

7 wherein the medicament is formulated to be subcutaneously administered as a first
8 dose of the antibody on week 0 and a subsequent dose at every 12 weeks after the first dose;

9 wherein the medicament is formulated to be administered as a subsequent dose at
10 every 12 weeks at least up to 52 weeks; and

11 wherein an ACR20 response value of at least 40% at week 24 or week 52 indicates the
12 efficacy of the antibody.

1 8. The use according to claim 7, wherein an ACR20 response value of at least 50% at
2 week 24 or week 52 indicates the efficacy of the antibody.

1 9. The use according to claim 7, wherein an ACR20 response value of at least 60% at
2 week 24 or week 52 indicates the efficacy of the antibody.

1 10. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:

3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
4 1; and

5 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
6 2;

7 wherein the medicament is formulated to be subcutaneously administered as a first
8 dose of the antibody on week 0 and a subsequent dose at every 12 weeks after the first
9 dose;

10 wherein the medicament is formulated to be administered as a subsequent dose at
11 every 12 weeks at least up to 52 weeks; and

12 wherein an ACR50 response value of at least 20% at week 24 or week 52 indicates the
13 efficacy of the antibody.

1 11. The use according to claim 10, wherein an ACR50 response value of at least 25% at
2 week 24 or week 52 indicates the efficacy of the antibody.

1 12. The use according to claim 10, wherein an ACR50 response value of at least 30% at
2 week 24 or week 52 indicates the efficacy of the antibody.

1 13. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:

- 3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO:
4 1; and
- 5 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
6 2;
- 7 wherein the medicament is formulated to be subcutaneously administered as a first
8 dose of the antibody on week 0 and a subsequent dose at every 12 weeks after the first
9 dose;
- 10 wherein the medicament is formulated to be administered as a subsequent dose at
11 every 12 weeks at least up to 52 weeks; and
- 12 wherein an ACR70 response value of at least 10% at week 24 or week 52 indicates the
13 efficacy of the antibody.
- 1 14. The use according to claim 13, wherein an ACR70 response value of at least 12% at
2 week 24 or week 52 indicates the efficacy of the antibody.
- 1 15. The use according to claim 13, wherein an ACR70 response value of at least 15% at
2 week 24 or week 52 indicates the efficacy of the antibody.
- 1 16. The use according to any one of claims 1-15, wherein the first dose and the subsequent
2 dose are same.
- 1 17. The use according to any one of claims 1-15, wherein the first dose and the subsequent
2 dose are different.
- 1 18. The use according to any one of claims 1-15, wherein the first dose is 100 mg.
- 1 19. The use according to any one of claims 1-15, wherein the first dose is 200 mg.
- 1 20. The use according to any one of claims 1-15, wherein the subsequent dose is 100 mg.
- 1 21. The use according to any one of claims 1-15, wherein the subsequent dose is 200 mg.
- 1 22. The use according to any one of claims 1-15, wherein the first dose and the subsequent
2 dose are 100 mg.
- 1 23. The use according to any one of claims 1-15, wherein the first dose and the subsequent
2 dose are 200 mg.
- 1 24. The use according to any one of claims 1-15, wherein the first dose is 100 mg and the
2 subsequent dose is 200 mg.

- 1 25. The use according to any one of claims 1-15, wherein the first dose is 200 mg and the
2 subsequent dose is 100 mg.
- 1 26. The use according to any one of claims 1-15, wherein the medicament is formulated to be
2 administered as a subsequent dose at every 12 weeks at least up to 60 weeks.
- 1 27. The use according to any one of claims 1-15, wherein the medicament is formulated to be
2 administered as a subsequent dose at every 12 weeks at least up to 72 weeks.
- 1 28. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:
- 3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1;
4 and (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID
5 NO: 2;
- 6 wherein the medicament is formulated to be subcutaneously administered as a first
7 dose of the antibody on week 0 and a subsequent dose at every 12 weeks after the first
8 dose;
- 9 wherein the medicament is formulated to be administered as a subsequent dose at
10 every 12 weeks at least up to 52 weeks; and
- 11 wherein at least a 75% improvement from baseline value in Psoriasis Area and
12 Severity Index at week 52 indicates the efficacy of the antibody.
- 1 29. The use according to claim 28, wherein at least 90% improvement from baseline value
2 in Psoriasis Area and Severity Index at week 52 indicates the efficacy of the antibody.
- 1 30. The use according to claim 28, wherein at least 100% improvement from baseline
2 value in Psoriasis Area and Severity Index at week 52 indicates the efficacy of the antibody.
- 3 31. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
4 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:
- 5 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1;
6 and
- 7 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
8 wherein the medicament is formulated to be subcutaneously administered as a first
9 dose of the antibody on week 0 and a subsequent dose at every 12 weeks after the first
10 dose;

11 wherein the medicament is formulated to be administered as a subsequent dose at
12 every 12 weeks at least up to 52 weeks; and
13 wherein a reduced DAS28-CRP score from baseline value at week 52 indicates the
14 efficacy of the antibody.

1 32. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for
2 the treatment of psoriatic arthritis, wherein the antibody hum13B8-b comprises:

3 (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1;
4 and
5 (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
6 wherein the medicament is formulated to be subcutaneously administered as a first
7 dose of the antibody on week 0 and a subsequent dose at every 12 weeks after the first
8 dose;
9 wherein the medicament is formulated to be administered as a subsequent dose at
10 every 12 weeks at least up to 52 weeks; and
11 wherein a statistically significant improvement in disease activity as determined by the
12 minimal disease activity (MDA) criteria at week 52 indicates the efficacy of the
13 antibody.